1 / 29

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. 부산백병원 산부인과 R2 서영진. BACKGROUND. Ovarian cancer - leading cause of the death in USA Standard chemotherapy for the initial Tx - combination of a platinum analogue with paclitaxel - with modern surgical intervention

arav
Télécharger la présentation

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer 부산백병원 산부인과 R2 서영진

  2. BACKGROUND • Ovarian cancer - leading cause of the death in USA • Standard chemotherapy for the initial Tx - combination of a platinum analogue with paclitaxel - with modern surgical intervention : attain clinical remission  however, relapse and die of the disease • The rationale for intraperitoneal CTx - the peritoneum receives sustained exposure to high concentrations of antitumor agents while normal tissues are relatively spared

  3. Theory of IP approach • High IP concentration of drug • Longer half-life of drug in abdominal cavity than with IV administration • Prolonged systemic exposure • IP chemotherapy not effective in bulky disease; should be targeted at women with no residual or minimal residual disease • Chemotherapeutic agents with higher molecular weight had longer half-lives • Platinums/ taxanes have 10-20 times greater concentration IP than when given IV

  4. Intraperitoneal(IP) chemoTx - high cost, toxicity, cilnicians’ lack of familiarity with peritoneal administration, cathrter-placement technique

  5. Development of IP CTx • 1950’s: First use of intraperitoneal chemotherapy for malignant ascites • 1968: Long-term peritoneal access device • 1978: Demonstration of slow peritoneal clearance of some drugs • 1984: Feasibility of intermittent large volume intraperitoneal therapy • 1996: First report of a survival benefit for IP vs. IV chemotherapy in advanced ovarian cancer

  6. IV paclitaxel + IV cisplatin (6 cycle) VS. IV paclitaxel + IP cisplatin / IP paclitaxel (6 cycle)

  7. METHODS (patient) • Stage III epithelial ovarian or peritoneal carcinoma - no residual mass (<1.0cm) after surgery - GOG performance status of 0 to 2 - normal CBC, adequate renal & hepatic function • At registration - decide the 2nd-look laparotomy at the completion of chemotherapy • Before each Tx - PEx, Hx, CBC, chemistry, CA125 (every 3 months for 24 months and then every 6 months)

  8. Quality-of-life assessment (FACT-O) - at registration before cycle 4 3 to 6 weeks after cycle 6 12 months after the completion of therapy

  9. METHODS (treatment plan) • IV group - day 1: IV paclitaxel 135 mg/m2 day 2: IV cisplatin 75 mg/m2 • IP group - day 1 : IV paclitaxel 135 mg/m2 day 2 : IP cisplatin 100 mg/m2 day 8 : IP paclitaxel 60 mg/m2 • Standard premedication - hydration & antiemetics before cisplatin - reconstituted IP agent with 2 liter warmed N/S

  10. DAY 0 - Dexamethasone 20 mg PO • DAY 1 - Paclitaxel 135 mg/m2 IV (3 hours) : 6시간 전 Dexamethasone 20 mg PO (or 30분 전 Dexamethasone 10~20 mg IV) : 30~60분 전 Ranitidine 50 mg IV Diphenhydramine 50 mg IV

  11. DAY 2 - Palonosetron 250 mcg IV Dexamethasone 12 mg IV/PO Aprepitant 135 mg PO - hydration before cisplatin : N/S 1000ml (350ml/hr) : output > 100mg/hr - cisplatin 75mg/m2 IP in 2L saline : need a bed,lie flat, slight head elevation : ascites should be drained - hydration after cisplatin : N/S 350ml/hr x 5 hrs

  12. DAY 3 - Dexamethasone 12 mg PO Aprepiant 80 mg PO in AM • DAY 4 - Dexamethasone 12 mg PO Aprepiant 80 mg PO in AM • DAY 8 - Paclitaxel 60mg/m2 IP in 2L saline 30분전 Dexamethasone 10mg IV 30~60분 전 Ranitidine 50mg IV Diphenhydramine 50mg IV

  13. Before the treatment - ANC > 1,500 PLT > 100,000 Cr < 2.0 Ccr < 50 hepatic toxicity, peripheral neuropathy → if not, cycle delay, dose reduction, G-CSF • 2nd-look laparotomy - 8 weeks after the last cycle negative : complete response positive : microscopic or grossly visible

  14. Dose of IP CTx - grade 2 abd. pain, neuropathy • If grade 3 abd. pain , recurrent grade 2 abd. pain complication s involving the IP catheter - IV CTx for the remaining cycle • Cisplatin-related complication - carboplatin substituted for cisplatin

  15. METHODS (statistical analysis) • Overall survival - survival was measured up to the date of death or, for living patients, the date of last contact • Progression-free survival - until progression, death, or the date of last contact

  16. RESULTS (patients) • March 1998 ~ January 2001 • IV group : 215 patients IP group : 214 patients • Ineligible patients (14 patients) - IV group (5), IP group (9) - stage > III second primary cancer nonepithelial cell type other primary cancer inadequate surgery low malignant potential

  17. RESULTS (toxicity) • Intolerable toxic effects related cisplatin - drug was switched to IV carboplatin • Primary reason for discontinuation of IP CTx - catheter-related complications • All treatment-related deaths were attributed infection

  18. RESULTS (pathologic responses at second-look laparotomy) • Laparotomy was not mandatory • IV group - 102 patients : 41% complete pathological responses • IP group - 100 patients : 57% complete pathological responses

  19. RESULTS (survival) • The median duration of follow-up - IV group : 48.2 months IP group : 52.6 months • Median progression-free survival - IV group : 18.3 months IP group : 23.8 months • Median overall survival - IV group : 49.7 months IP group : 65.6 months

  20. Mean FACT-O quality-of-life score - IP group reported lower scores than IV group - but, no significant differences between the groups 1 year after tretment

  21. DISCUSSION • IP CTx significantly improved progression-free survival and overall survival - IP CTx had a 25% reduction in the risk of death • In a previous GOG study - doubling dose of IV cisplatin & cyclophosphamide - increasing dose density or intensity  limitation

  22. Toxic events - IP group > IV group - may be attributed to the higher cisplatin • Paclitaxel - persists in the peritoneum for 1 week - peritoneal clearance is very slow - peritoneal clearance is altered when drug is given after IP cisplatin - increase toxicity

  23. IP CTx toxic effects - catheter-related : substantial portion - catheter type & the timing of catheter replacement were not specified - standardization of the device : improve the success of IP CT

  24. Conclusion - IP CTX has a clinical advantage in the ovarian ca - but, toxicity ↑ & quality of life ↓ - Use of IP CTx in patients with advanced ovarian cancer

  25. CONSENSUS: 2005 • The toxicities, inconvenience and cost of IP therapy are justified by the improved survival seen with this treatment • New, targeted therapies are likely to be more effective in patients who have an excellent response to chemotherapy • While we work to improve the tolerability and toxicities of IP therapy, it remains the most effective means of treating ovarian cancer today

More Related